Related Experiment Video

Updated: May 17, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

ADRB3 and PPARγ2 gene polymorphisms and their association with cardiovascular disease risk in postmenopausal women

F Lwow1, K Dunajska, A Milewicz

  • 1Department of Health Promotion, Faculty of Physiotherapy, University School of Physical Education, Wroclaw, Poland.

Climacteric : the Journal of the International Menopause Society
|November 2, 2012
PubMed

Insights

Cardiovascular disease (CVD) risk factors are not directly linked to ADRB3 and PPARγ2 gene variations in postmenopausal women. However, PPARγ2 gene polymorphism may indirectly influence CVD risk through increased body fat.

Area of Science:

  • Genetics and Molecular Biology
  • Cardiovascular Disease Research
  • Metabolic Syndrome

Background:

  • Cardiovascular disease (CVD) development is influenced by genetic factors, prompting research into specific gene polymorphisms.
  • Understanding genetic susceptibility can lead to personalized clinical interventions for CVD.
  • Postmenopausal women represent a demographic with increased CVD risk, making them a key study group.

Purpose of the Study:

  • To investigate the association between polymorphisms in the ADRB3 and PPARγ2 genes and CVD risk factors in postmenopausal women.
  • To explore the relationship between these gene polymorphisms, obesity indices, lipid profiles, and insulin resistance.

Main Methods:

  • A study involving 343 postmenopausal women.
  • Analysis of associations between ADRB3 and PPARγ2 gene polymorphisms and obesity indices.
  • Evaluation of lipid profile parameters and the Homeostatic Model Assessment (HOMA) for insulin resistance.

Main Results:

  • No direct association was found between tested polymorphisms (ADRB3, PPARγ2) and common CVD risk factors like high cholesterol, low HDL, high LDL, or high triacylglycerols.
  • Arterial hypertension and elevated HOMA values were not significantly related to the studied gene polymorphisms.
  • A significant association was observed between PPARγ2 gene polymorphism (Pro12Ala allele) and increased total body fat mass (OR=1.90) and android fat deposit mass (OR=1.82).

Conclusions:

  • The polymorphisms of PPARγ2 and ADRB3 genes are not directly associated with major CVD risk factors in postmenopausal women.
  • An indirect link between PPARγ2 gene polymorphism and CVD susceptibility in this population may exist.
  • The association of PPARγ2 polymorphism with higher body fat mass suggests a potential indirect pathway influencing CVD risk.
Abstract

More Related Videos

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease09:38

Generalized Psychophysiological Interaction (PPI) Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease

Published on: November 14, 2017

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...